Business Wire
20 Jul 2026, 08:00 UTC · 17h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
The European Medicines Agency (EMA) has accepted the submission to extend the Marketing Authorisation Application of Ebglyss (lebrikizumab) to children and adolescents aged 6 months and older. — Expanding the eligible patient demographic for a key product increases potential revenue streams and market penetration.
+0.40Which stocks this story touches
The company's application to expand the treatment use of Ebglyss to children and adolescents was accepted by the EMA.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
20h ago
